Suppr超能文献

外泌体微小RNA在恶性胆道梗阻患者胆汁中的诊断价值

The diagnostic value of exosomal miRNAs in human bile of malignant biliary obstructions.

作者信息

Ge Xianxiu, Tang Lingyu, Wang Youli, Wang Ni, Zhou Jian, Deng Xueting, Zhong Yuan, Li Quanpeng, Wang Fei, Jiang Guobin, Miao Lin

机构信息

Institute of Digestive Endoscopy and Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Department of Clinical Laboratory, Nanjing First Hospital, Nanjing, China.

出版信息

Dig Liver Dis. 2021 Jun;53(6):760-765. doi: 10.1016/j.dld.2020.11.010. Epub 2020 Nov 27.

Abstract

BACKGROUND

Diagnosis of malignant biliary obstruction is complicated and lacks accuracy. Exosomes may be secreted by malignant tumors; intact miRNAs from exosomes might serve as potential biomarkers for the disease.

AIM

To identify exosomal microRNAs in human bile among benign and malignant biliary obstructions.

METHODS

Bile samples were collected from patients undergoing therapeutic endoscopic retrograde cholangiopancreatography for biliary obstruction. Exosome microRNAs were determined by RNA-sequencing in the discovery cohort, which comprising benign (n = 5) cases and malignant biliary obstruction (n = 5) cases. Then, the diagnostic performance of the two up-regulated microRNAs (mir-483-5p and mir-126-3p) of bile exosomes was verified by analysis of 82 patients with a diagnosis of malignant (n=37) or nonmalignant (n=45) biliary obstruction.

RESULTS

In both cohorts, the expressions of mir-483-5p and mir-126-3p were significantly higher in bile exosomes samples from patients with malignant biliary obstructions than controls. In the verification cohort, the two miRNAs can distinguished the benign and malignant groups with high diagnostic accuracy and specificity; the diagnostic values of the two microRNAs were better than serum carbohydrate antigen 19-9 (CA19-9), area under the curve (AUC) were 0.81 and 0.74.

CONCLUSION

The expression of exosomal mir-483-5p and mir-126-3p in the bile samples discriminates between patients with malignant and nonmalignant biliary obstructions.

CLINICAL TRIAL REGISTRATION NO

NCT03102268.

摘要

背景

恶性胆道梗阻的诊断复杂且缺乏准确性。外泌体可能由恶性肿瘤分泌;外泌体中完整的微小RNA可能成为该疾病的潜在生物标志物。

目的

鉴定良性和恶性胆道梗阻患者胆汁中的外泌体微小RNA。

方法

收集因胆道梗阻接受治疗性内镜逆行胰胆管造影术患者的胆汁样本。在发现队列中通过RNA测序测定外泌体微小RNA,该队列包括良性(n = 5)病例和恶性胆道梗阻(n = 5)病例。然后,通过分析82例诊断为恶性(n = 37)或非恶性(n = 45)胆道梗阻的患者,验证胆汁外泌体中两种上调的微小RNA(mir - 483 - 5p和mir - 126 - 3p)的诊断性能。

结果

在两个队列中,恶性胆道梗阻患者胆汁外泌体样本中mir - 483 - 5p和mir - 126 - 3p的表达均显著高于对照组。在验证队列中,这两种微小RNA能够以高诊断准确性和特异性区分良性和恶性组;这两种微小RNA的诊断价值优于血清糖类抗原19 - 9(CA19 - 9),曲线下面积(AUC)分别为0.8 和0.74。

结论

胆汁样本中外泌体mir - 483 - 5p和mir - 126 - 3p的表达可区分恶性和非恶性胆道梗阻患者。

临床试验注册号

NCT03102268。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验